1 |
Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.
DOI
ScienceOn
|
2 |
McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007; 13: 716s-20s.
DOI
ScienceOn
|
3 |
Molina AM, Motzer RJ. Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow. The oncologist 2011; 16:45.
DOI
ScienceOn
|
4 |
Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-96.
DOI
ScienceOn
|
5 |
Thompson Coon J, Hoyle M, Green C, et al., Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-184, iii-iv.
|
6 |
World Health Organization (WHO), Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals, In: Report of CIOMS Working Group IV; Geneva: 1998.
|
7 |
Escudier B, Pluzanska A, Koralewski P, et al., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
DOI
ScienceOn
|
8 |
Hudes G, Carducci M, Tomczak P, et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81
DOI
ScienceOn
|
9 |
Motzer RJ, Hutson TE, Tomczak P, et al., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Clin Oncol 2009; 27: 3584-90.
DOI
ScienceOn
|
10 |
Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010; 102: 80-6.
DOI
ScienceOn
|